Hancox JC - Search Results

1

The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias.

Curtis MJ, Hancox JC, Farkas A, Wainwright CL, Stables CL, Saint DA, Clements-Jewery H, Lambiase PD, Billman GE, Janse MJ, Pugsley MK, Ng GA, Roden DM, Camm AJ, Walker MJ. Curtis MJ, et al. Among authors: hancox jc. Pharmacol Ther. 2013 Aug;139(2):213-48. doi: 10.1016/j.pharmthera.2013.04.008. Epub 2013 Apr 12. Pharmacol Ther. 2013. PMID: 23588158

2

Preparation, preparation, preparation: The influence of adrenergic agonism in cardiac ventricular repolarisation assays used in preclinical drug development and drug safety pharmacology.

Hancox JC, Curtis MJ. Hancox JC, et al. J Pharmacol Toxicol Methods. 2005 Mar-Apr;51(2):77-9. doi: 10.1016/j.vascn.2004.11.001. Epub 2004 Dec 9. J Pharmacol Toxicol Methods. 2005. PMID: 15767200 No abstract available.

3

Methods for screening drugs for their pro-arrhythmic liability: does the rabbit ventricular wedge hold the key?

Hancox JC, Curtis MJ. Hancox JC, et al. J Pharmacol Toxicol Methods. 2006 Nov-Dec;54(3):257-60. doi: 10.1016/j.vascn.2006.04.003. Epub 2006 Apr 27. J Pharmacol Toxicol Methods. 2006. PMID: 16781874 No abstract available.

4

Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.

Pugsley MK, Hancox JC, Curtis MJ. Pugsley MK, et al. Among authors: hancox jc. Pharmacol Ther. 2008 Aug;119(2):115-7. doi: 10.1016/j.pharmthera.2008.05.004. Epub 2008 Jun 10. Pharmacol Ther. 2008. PMID: 18590766

5

The hERG potassium channel and hERG screening for drug-induced torsades de pointes.

Hancox JC, McPate MJ, El Harchi A, Zhang YH. Hancox JC, et al. Pharmacol Ther. 2008 Aug;119(2):118-32. doi: 10.1016/j.pharmthera.2008.05.009. Epub 2008 Jun 18. Pharmacol Ther. 2008. PMID: 18616963 Review.

6

hERG potassium channel inhibition by ivabradine requires channel gating.

Melgari D, Brack KE, Zhang Y, El Harchi A, Mitcheson JS, Dempsey CE, Ng GA, Hancox JC. Melgari D, et al. Among authors: hancox jc. J Mol Cell Cardiol. 2015 Oct;87:126-8. doi: 10.1016/j.yjmcc.2015.08.002. Epub 2015 Aug 11. J Mol Cell Cardiol. 2015. PMID: 26275355 No abstract available.

7

hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes.

Hancox JC, Melgari D, Dempsey CE, Brack KE, Mitcheson J, Ng GA. Hancox JC, et al. Ther Adv Drug Saf. 2015 Aug;6(4):177-9. doi: 10.1177/2042098615595546. Ther Adv Drug Saf. 2015. PMID: 26301071 Free PMC article. No abstract available.

8

Letter by Melgari et al Regarding Article, "Ivabradine: Role in the Chronic Heart Failure Armamentarium".

Melgari D, Ng GA, Hancox JC. Melgari D, et al. Among authors: hancox jc. Circulation. 2016 Sep 27;134(13):e296-7. doi: 10.1161/CIRCULATIONAHA.116.023752. Circulation. 2016. PMID: 27672201 No abstract available.

9

Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.

McPate MJ, Duncan RS, Hancox JC, Witchel HJ. McPate MJ, et al. Among authors: hancox jc. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25. Br J Pharmacol. 2008. PMID: 18724381 Free PMC article.

10

Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias.

O'Leary ME, Hancox JC. O'Leary ME, et al. Among authors: hancox jc. Br J Clin Pharmacol. 2010 May;69(5):427-42. doi: 10.1111/j.1365-2125.2010.03629.x. Br J Clin Pharmacol. 2010. PMID: 20573078 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page